Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to GS-9883/emtricitabine/tenofovir alafenamide versus continue boosted atazanavir or darunavir regimens in virologically suppressed adults with HIV-1
2015-004011-20Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bictegravir, emtricitabine and tenofovir alafenamide in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Virologic failure at Week 48. Started Nov 2015; status: completed.
02
Drugs
bictegraviremtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2015-004011-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004011-20.